Oncogene-Targeting T Cells Reject Large Tumors while Oncogene Inactivation Selects Escape Variants in Mouse Models of Cancer  by Anders, Kathleen et al.
Cancer Cell
ArticleOncogene-Targeting T Cells Reject Large Tumors
while Oncogene Inactivation Selects Escape
Variants in Mouse Models of Cancer
Kathleen Anders,1 Christian Buschow,2 Andreas Herrmann,4 Ana Milojkovic,5 Christoph Loddenkemper,3
Thomas Kammertoens,2 Peter Daniel,5 Hua Yu,4 Jehad Charo,1 and Thomas Blankenstein1,2,*
1Max-Delbru¨ck-Center for Molecular Medicine, 13092 Berlin, Germany
2Institute of Immunology
3Institute of Pathology
Charite´ Campus Benjamin Franklin, 12200, Berlin, Germany
4Cancer Immunotherapeutics and Tumor Immunology, Beckman Research Institute, City of Hope Cancer Center, Duarte, CA 91010, USA
5Department of Hematology, Oncology and Tumor Immunology, Charite´ Campus Berlin Buch, 13092 Berlin, Germany
*Correspondence: tblanke@mdc-berlin.de
DOI 10.1016/j.ccr.2011.10.019SUMMARYThe genetic instability of cancer cells frequently causes drug resistance. We established mouse cancer
models, which allowed targeting of an oncogene by drug-mediated inactivation or monospecific CD8+
effector T (TE) cells. Drug treatment of genetically unstable large tumors was effective but selected resistant
clones in the long term. In contrast, TE cells completely rejected large tumors (R500 mm
3), if the target
antigen was cancer-driving and expressed in sufficient amounts. Although drug-mediated oncogene inacti-
vation selectively killed the cancer cells and left the tumor vasculature intact, which likely facilitated survival
and growth of resistant clones, TE cell treatment led to blood vessel destruction and probably ‘‘bystander’’
elimination of escape variants, which did not require antigen cross-presentation by stromal cells.INTRODUCTION
One of the hallmarks of cancer is a high degree of genetic insta-
bility and the accumulation of somatic mutations. In colorectal
cancers, for example, up to 10,000 somatic mutations have
been detected (Stoler et al., 1999). The high mutation rate in
tumors may explain the frequently observed resistance to
chemotherapy or drugs interfering with oncogene activity
(Gorre et al., 2001; Knight et al., 2010; Pao et al., 2005). In the
clinic, tumors can be detected at about 1 cm in diameter
(500 mm3), which corresponds to approximately 109 tumor
cells (Schreiber et al., 2006; Kumar et al., 2004). Anticancer
drug efficacy depends on the number of cancer cells and,
thus, the number of genetic variants at the time of treatment
(Skipper, 1965). Drug and T cell therapy were usually analyzed
against small tumors below size that can be detected in the clinicSignificance
So far, the genetic instability of cancer cells impedes effective
tively transferred T cells. We created ideal conditions to target t
both induced regression of large tumors. Yet, only T cell thera
also destroyed the tumor vasculature. Because techniques fo
pressed in human tumors have recently been developed, defi
future clinical trials.
Can(Schreiber et al., 2006), and their efficacy was never compared in
the same tumor model.
If resistance to chemotherapy or oncogene-inactivating drugs
is due to selection of mutant clones caused by genetic instability,
onewould expect that otherwise effective adoptive T cell therapy
similarly selects variants that escape T cell-mediated destruction
(Liu and Bai, 2008). Antigen loss variants were found in patients
withmelanoma after T cell therapy (Restifo et al., 1996; Yee et al.,
2000), suggesting that T cell therapy is as vulnerable to selection
of escape variants as therapy with oncogene-inactivating drugs.
However, in some experimental models, adoptively transferred
T cells could reject large tumors (defined as R500 mm3) (Kast
et al., 1989; Spiotto et al., 2004). Sufficient amounts of tumor
antigen expression for cross-presentation by tumor stroma cells
and T cell-derived interferon-g (IFN-g) acting on stroma hindered
outgrowth of antigen loss variants (Spiotto et al., 2004; Zhangtherapy with oncogene inactivating drugs as well as adop-
he oncogene by drug-mediated inactivation or T cells, which
py resulted in long-term cure, probably because the T cells
r therapy with high-avidity T cells against antigens overex-
ning optimal conditions for T cell therapy may help improve
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Figure 1. Drug-Mediated Oncogene Inactivation in Large Tumors Induces Transient Tumor Regression
(A) Tet-TagLuc fibrosarcoma cells were generated by infection of primary fibroblasts of a TREloxPstoploxPTagLuc transgenic mouse with a Cre-encoding
adenovirus (AdCre) to excise the stop cassette, a Tet-off transactivator-encoding retrovirus (RvtTA), and adaptation to in vivo growth at passage 19 (p19).
Expression of the TagLuc fusion gene can be regulated by dox.
(B) Tet-TagLuc cells (1 3 104) in duplicates were cultured with (0.5 mg/ml) or without dox, and cell numbers were determined daily for 4 days. Error bars
represent ±SD.
(C) Rag/mice with established Tet-TagLuc tumors (mean ± SD, 546 ± 246 mm3 at 30 days) received dox-containing drinking water, and TagLuc expression
was followed by BL imaging (1 s exposure time). The time after treatment is indicated in days (d).
(D) BL signals of dox-treated tumors of individual mice (n = 8) were quantified over time.
(E) Tumor growth kinetics is displayed for mice shown in (D). Results in (C–E) are representative for three experiments with a total of 12 analyzed mice.
(F) Tumor growth kinetics of individual mice (n = 7) with small Tet-TagLuc tumors (%250 mm3) treated with dox are shown in the left panel. Time point of dox
treatment is indicated. For comparison, the mice with large tumors as in (E) are shown (right panel). The number of mice with tumor relapse is indicated.
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Overcoming Genetic Instability of Canceret al., 2008). The mode of tumor destruction may be different for
drug and T cell therapy that, however, has not been addressed
in a clinically relevant (e.g., large) tumor model. Here, we estab-
lished a mouse cancer model allowing direct comparison of
the efficacy of drug versus T cell therapy directed against the
same target protein to eradicate large established tumors.
SV40 large T antigen (Tag) is a well-characterized oncogene
with defined H-2b restricted epitopes (Staveley-O’Carroll et al.,
2003). Tag, among other activities, inactivates the tumor
suppressors p53 and retinoblastoma protein (Rb), reducing
DNA repair and creating a genetically unstable phenotype (Kuer-
bitz et al., 1992).756 Cancer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier IncRESULTS
Generation of a Conditional TagLuc Expressing Tumor
Cell Line in Mice
To compare the therapeutic efficacy of drug-mediated onco-
gene inactivation and targeting the oncogene by single peptide
antigen-specific CD8+ effector (TE) cells, we isolated fibroblasts
from a TREloxPstoploxPTagLuc transgenic mouse (Figure 1A),
which contains the Tag gene fused to the firefly luciferase (Luc)
gene by a linker, encoding glycine-serine (G4S)3 repeats
(TagLuc). Expression of the TagLuc fusion gene in TREloxP
stoploxPTagLuc mice is regulated by a tetracycline response.
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Figure 2. Each Dox-Unresponsive Tumor Reveals a Unique Point Mutation in the Transactivator Gene
(A) Parental Tet-TagLuc cells and cells of three dox-unresponsive tumors were cultured for 5 days in the presence of dox (1 mg/ml), and TagLuc expression was
analyzed by western blot analysis with an anti-Tag antibody. As loading control, b-actin was detected.
(B) Relative light units (RLU) were analyzed in parental and drug-resistant Tet-TagLuc cells, cultured in the presence or absence of dox. One of three analyzed
dox-unresponsive tumors with similar results is shown. Error bars represent ±SD.
(C) Comparison of the tTA amino acid (AA) sequence from position 64 to182 of parental Tet-TagLuc cells (top) and seven dox-unresponsive tumors (tumor 2 and 6
with two mutations). Mutations are shown in bold. Mutations in the tTA leading to dox-unresponsive variants are indicated by a black circle.
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vator (TA) (Gossen and Bujard, 2002). A loxP-flanked stop
cassette (between TRE and TagLuc) was excised by transient
adenoviral Cre recombinase (AdCre) expression in the primary
cells (Figure 1A). Subsequent introduction of a Tet-off transacti-
vator (tTA) by stable gene transfer with a tTA-encoding retrovirus
allowed TagLuc expression, reversible by adding doxycycline
(dox) (see below). TagLuc-expressing cells at passage 19 of
in vitro culture exhibited immortal growth and were adapted to
tumor growth in vivo. The resulting cell line, termed Tet-TagLuc,
proliferated only in absence of dox (Figure 1B).
TagLuc Inactivation Fails to Control Large Tumors
in the Long Term
Micewith large Tet-TagLuc tumors (546 ± 246mm3) were treated
with dox, and the kinetics of TagLuc inactivation were followed
by bioluminescence (BL) imaging. After 1 day, a decrease of
BL signal, declining on day 3 below detectable level at 1 s expo-
sure time, was observed, followed by tumor regression. Then,
despite further dox treatment, the BL signal reappeared and
tumors progressively grew in all cases (Figures 1C–1E). AnalysisCanof the efficacy of dox in treating smaller (%250 mm3) tumors
showed that most tumors could still be eliminated (Figure 1F),
indicating that selection of dox-unresponsive variants that likely
occur at a low rate requires large numbers of tumor cells.
Each Dox-Unresponsive Tumor Reveals a Unique Point
Mutation in the Transactivator Gene
Tumors that grew in the presence of dox were analyzed in vitro.
Although dox treatment of the original Tet-TagLuc cells resulted
in loss of TagLuc expression, as shown by western blot and BL
analysis, the variant cell lines did not reduce TagLuc expression
in response to dox (Figures 2A and 2B), suggesting genetically
acquired resistance. These data argued against the possibility
that the therapy selected variant cancer cells that lost the onco-
gene dependence (Jonkers and Berns, 2004; Weinstein, 2002),
but rather pointed to the inability of dox to bind to and inactivate
the tTA. The amino acid positions in the tTA allowing dox binding
are well characterized (Hillen and Berens, 1994; Hinrichs et al.,
1994). DNA sequence analysis of seven dox-unresponsive
tumors showed in five cases a single point mutation in the tTA
gene (Figure 2C). Two tumors had two point mutations each,cer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Inc. 757
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Figure 3. Partial Compensation of Selection
of Dox-Unresponsive Tumors by Endoge-
nous T Cells
(A) Scheme of the experimental design. The mice,
which rejected the tumor, received two albino B6
skin grafts expressing either the Luc or the rtTA
transgene, both shared with the tumor cells.
(B) Expansion of transferred CD8+ T cells was
determined 5 and 19 days after dox treatment by
determining the percentage of transferred (Vb5)
out of total CD8+ T cells (mean ± SD, 4.41 ± 1.64
versus 9.56 ± 1.9; n = 3).
(C) BL signals of tumors (mean ± SD, 892 ±
237 mm3) were determined over time. (A) Spleen
cell transfer and dox-treatment (n = 12); (B) spleen
cell transfer without dox-treatment (n = 3); (>) dox
treatment but no spleen cell transfer (n = 2).
(D) Tumor growth kinetics of mice shown in (C).
Numbers of mice with rejected or relapsed tumors
are indicated.
(E) Photographs (upper panel) and pictures of BL
measurement (middle panel) of Luc+ (right) and
rtTA+ skin grafts (left) transplanted on either
C57Bl/6 mice (left), Rag//OT-1 mice recon-
stituted with Tag-tolerant splenocytes that did not
(middle) or did receive and reject a tumor after dox
treatment (right). Pictureswere acquiredmore than
3 months after skin transplantation. One repre-
sentative example of eachgroup is shown.Number
of graft rejections/number of mice in experiment
and time of graft rejection in days (d) is given.
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to amino acid substitutions in positions known to be binding sites
of dox or otherwise essential for tTA function (Hinrichs et al.,
1994). Importantly, each tumor had acquired the mutation at
a unique tTA-inactivating position or resulting in a different amino
acid replacement, showing the high instability of the cancer cells
with a seemingly unlimited reservoir of genetic variants in large
tumors.
Endogenous T Cells Only Partially Prevent Relapse
following TagLuc Inactivation
The previous experiments were performed in Rag/ mice
because the C57Bl/6 (B6)-derived Tet-TagLuc cells are rejected
in B6 mice as a result of the high immunogenicity of Tag. To ask
whether tumor cell death by TagLuc inactivation induced endog-
enous T cells that counteracted the selection of drug-resistant
clones, Rag//OT-1 mice bearing 22-day-old (small) tumors
received naive splenocytes (Figure 3A). Rag//OT-1 mice with
tumor-unrelated transgenic (ovalbumin-specific) T cells were
used to avoid homeostatic proliferation and nonspecific T cell
activation. Splenocytes from Tag-tolerant LoxP-Tag 3 Alb-Cre
mice were used, because transfer of naive B6 splenocytes led
to rejection of these tumors by spontaneously activated Tag-
specific TE cells (our unpublished observation). However, Tet-758 Cancer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Inc.TagLuc cells express at least two further
antigens, Luc and tTA that are foreign to
the T cells and could serve as rejection
antigens. Tumors in the presence of
LoxP-Tag 3 Alb-Cre splenocytes pro-gressively grew, showing that Luc and tTA are obviously too
weak antigens to spontaneously induce T cells in the reconsti-
tuted mice. Following dox treatment on day 34, the tumors
(R500 mm3) regressed as before, Vb5 (non-OT-1) CD8+
T cells expanded (Figure 3B), and half of the mice completely
rejected the tumor, whereas in the other half, BL signals
increased and the tumor resumed growth (Figures 3C and 3D).
In those mice that rejected the tumor, we analyzed whether
any of the two putative tumor antigens had induced T cells
because of TagLuc inactivation-induced tumor cell death, which
contributed to tumor rejection. Therefore, mice received two
skin grafts, either from CAG-FLuc or rtTA-CM2 transgenic
mice. In both cases, the transgene is expressed by the ubiqui-
tous CAG promoter. For better transplant visibility, albino
B6 mice were used as transgenic skin donors. T cell-reconsti-
tuted Rag//OT-1 mice that had not received Tet-TagLuc cells
long term accepted both skin grafts (Figure 3E). Naive B6 mice
rejected the rtTA but long term accepted the Luc skin graft. Re-
constituted Rag//OT-1 mice that had rejected Tet-TagLuc
tumors after dox-induced TagLuc inactivation rejected the rtTA
but not the Luc skin graft. In these mice, the rtTA skin graft
was rejected faster than in naive B6 mice, suggesting that
rtTA-specific memory T cells had been induced during tumor
cell death (Figure 3E). These data suggested that endogeneous
EA
CB
D
Figure 4. Complete Eradication of large
Genetically Unstable Tumors by Adoptive T Cell
Therapy with Single Peptide-Specific TE cells
(A) Rag/ mice with established Tet-TagLuc tumors
(mean ± SD, 837 ± 287 mm3) received 13 106 TCR-I TE
cells, and changes of TagLuc signal were followed by
BL imaging (1 s exposure time). The time after treatment
is indicated in days (d). See also Figure S1.
(B) BL signals of TE cell-treated tumors of individual
mice (n = 5) were measured over time.
(C) Tumor growth kinetics of mice shown in (B). Results
in (A–C) are representative for three experiments with
a total of 10 analyzed mice.
(D) Rag/ mice with established Tet-TagLuc tumors
(mean ± SD, 643 ± 82 mm3) were treated with dox, and
relapsed tumors (6/6) were subsequently treated by
TE cells (C; n = 4) or were left untreated (B; n = 2).
Changes in BL signal over time of individual mice are
shown.
(E) Tumor growth kinetics of mice shown in (D). One
representative of two experiments with a total of eight
double-treated mice is shown.
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inactivation, even though the tumor expressed a skin graft rejec-
tion antigen.
Complete Eradication of Large Tumors by Single
Peptide-Specific CD8+ Effector T Cells
Next, we asked whether adoptive T cell therapy with TE cells
directed against the epitope I of Tag (Staveley-O’Carroll et al.,
2003) also selected escape variants, when used to treat large
tumors. The epitope I region is dispensable for the transforming
activity of Tag, and epitope I loss variants ofmurine fibrosarcoma
cells could be selected in vitro by specific T cells (Mylin et al.,
2007). Also, H-2 loss variants of Tag-transformed cells were
found in transiently immune-suppressed mice (Gooding, 1982).
Thus, escape variants of Tet-TagLuc cells under TE cell pressure
appeared likely, in light of the high genetic instability and large
number of tumor cells at the time of treatment. Epitope I-specific
(purified TCR-I transgenic) TE cells (Figure S1 available online)
were transferred into mice with large established Tet-TagLuc
tumors (R500 mm3), and tumor regression was followed by BL
imaging. In contrast to dox treatment, no decrease in BL signal
was observed within the first 4 days after TE cell injection, and
tumors even increased in size (Figures 4A–4C). Then, betweenCancer Cell 20, 755–76days 5 and 6, the BL signal dramatically
decreased and became undetectable,
accompanied by hemorrhagic necrosis of
the tumor that was not seen in the dox-treated
tumors. TE cell-treated mice in all cases
completely rejected the tumor (Figure 4C). In
another experiment, mice with Tet-TagLuc
tumors were treated with dox as before and,
when large drug-resistant tumors had devel-
oped, were treated with TE cells, causing
complete and long-term tumor rejection in
all mice (Figures 4D and 4E). Thus, TE cells
with single peptide specificity reject largetumors, even those that had developed drug resistance, despite
large genetic instability.
TE Cells but Not TagLuc Inactivation Eradicates Gastric
Carcinomas in Mice
One cannot exclude that the effective TE cell treatment of Tet-
TagLuc tumors was because this cell line was generated by
in vitro transformation and had not undergone in vivo evolu-
tionary processes. Previously, we had observed in another trans-
genic mouse model with a dormant Tag oncogene that, by
stochastic rare events, sporadic tumors developed as a result
of somatic mutations or epigenetic events (Willimsky and
Blankenstein, 2005; Willimsky et al., 2008). Therefore, TREloxP
stoploxPTagLucmice were crossed to rtTA (tet-on) transactivator
transgenic (rtTA-CM2) mice. A small cohort of double transgenic
mice (with the stop cassette present) was kept on dox, and BL
signals were determined over time (Figure 5A). A distinct BL
signal appeared in one mouse after 411 days of dox treatment
that derived from a sporadic gastric carcinoma that was Luc
and Tag positive (Figures 5B and 5C). Proliferation of a cell line
(TC200.09) derived from this tumor depended on the presence
of dox (Figure 5D). Large established TC200.09 tumors were
treated with dox withdrawal or TE cells. TagLuc inactivation led7, December 13, 2011 ª2011 Elsevier Inc. 759
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Figure 5. Drug but Not TE Cell Resistance of
Gastric Carcinoma and Dependence of T Cell
Therapy on TagLuc Expression Level
(A) Sporadic tumor development was monitored in a
TREloxPstoploxPTagLuc+//rtTA-CM2+/ double transgenic
mouse by BL imaging. Time after starting dox adminis-
tration in days (d) is indicated.
(B) A tumor, located on the outer wall of the stomach
fundus, was isolated from the mouse shown in (A). A
photograph (upper panel) and a BL image (lower panel)
were acquired ex vivo.
(C) A section of the isolated stomach tumor was stained
with anti-Tag antibodies (scale bar, 100 mm).
(D) Proliferation of 1 3 104 cells (TC200.09) from the
stomach tumor was analyzed in the presence and absence
of dox in duplicates for 4 days. Standard deviation (SD) is
indicated.
(E) Rag/ mice with established TC200.09 tumors
(mean ± SD, 453 ± 110 mm3 at day 49) were left untreated
(B; n = 1) or treated by dox withdrawal (C; n = 9) and
tumor growth kinetics was determined.
(F) Rag/ mice with established TC200.09 tumors
(mean ± SD, 435 ± 100 mm3 at day 49) were left untreated
(B; n = 1) or were treated with TE cells (C; n = 10) and
tumor growth kinetics was determined. Arrows in (E and F)
indicate time point of treatment.
(G) TagLuc expression in MCA-TagLuc, TC200.09, and
Tet-TagLuc tumor cells was determined by quantifying
relative light units (RLU) in 5 3 105 cells (duplicates). Data
represent mean values from three independent experi-
ments (±SD).
(H) Rag/ mice with small MCA-TagLuc tumors (mean ±
SD, 166 ± 55 mm3 ten days after cell injection) received TE
cells as before and loss of TagLuc signal was followed by
BL imaging.
(I) BL signals of TE cell-treated (C; n = 8) or untreated
MCA-TagLuc tumors (B; n = 2) in individual mice were
measured over time.
(J) Tumor growth kinetics of mice shown in (I) shows
outgrowth of escape variants. Number of mice with tumor
rejection per total number of mice is indicated. One
representative of two experiments is shown. Error bars in
(D), (G), and (K) represent ±SD.
(K) RLU were analyzed in MCA205, parental MCA-TagLuc
cells and two tumors that escaped TE cell treatment.
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growth after more than 2 months, and in the other mice tumors
did not completely regress 80 days after treatment (Figure 5E).
Dox treatment of some of these mice (2/9) rapidly induced BL
signals (data not shown), suggesting incomplete tumor cell elim-
ination after TagLuc inactivation. In contrast, TE cells completely
rejected the tumor in all mice (Figure 5F).
Selection of Antigen Loss Variants by TE cells, if TagLuc
Is Not Cancer-Driving and Expressed in Lower Amounts
To ask whether epitope I-specific TE cells can select TagLuc-
negative variants in general, MCA-205 fibrosarcoma cells,
transfected to express 25- and 100-fold lower amounts of
the TagLuc antigen (MCA-TagLuc) in comparison to TC200.09
and Tet-TagLuc cells, respectively, were established (Figure 5G).
When mice with comparably small MCA-TagLuc tumors (166 ±
55 mm3) were treated with TE cells, BL signals disappeared after
5–6 days as before and tumors regressed (Figures 5H–5J). Then,
however, tumors resumed growth without proportional increase760 Cancer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Incin BL signal. These tumors had lost TagLuc expression, as veri-
fied by in vitro analysis (Figure 5K). Thus, if the target antigen is
expressed at lower level and/or is not cancer-driving, escape
variants are easily selected.
Different Mode of Tumor Cell Death by TagLuc
Inactivation and TE Cells
We searched for differences in tumor destruction induced by
TagLuc inactivation and TE cell treatment that can explain why
escape variants occurred upon drug but not TE cell treatment
of Tet-TagLuc tumors. Before treatment, tumors had a high-
grade pleomorphic sarcoma phenotype with few apoptotic cells
and many mitoses (Figure S2). Four days after dox treatment,
tumors had a fascicular growth pattern with spindle cell mor-
phology resembling low-grade fibrosarcoma. The cell density
decreased, and Tag and Luc expression were undetectable
apart from few focal areas, consistent with loss of expression
of the proliferation marker Ki-67 (Figure 6A). On day 7 after dox
treatment, almost no Tag- or Luc-positive cells were detected,.
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Figure 6. TE Cells Kill by Apoptosis Induc-
tion, Whereas TagLuc Inactivation Induces
Autophagy
(A) Consecutive Tet-TagLuc tumor sections were
stained with antibodies against Tag, luciferase, and
Ki-67 at the indicated days (d) after therapy. See
also Figure S2.
(B) Consecutive sections of untreated (n = 3), dox-
treated (day 1 after therapy; n = 3), or TE cell-treated
tumors (day 4 after therapy; n = 3) were stained with
HE and antibodies against cleaved Caspase 3
(cleaved-C3), Ki-67, and fibronectin. Scale bar in
(A) and (B), 100 mm.
(C) Quantification of Ki-67+ cells at different time
points after TagLuc inactivation.
(D) Quantification of cleaved-C3+ cells at different
time points after TagLuc inactivation. A total of
1,000 cells in five nonoverlapping high-power fields
were counted in (C) and (D) for each time point.
Three tumors per time point were analyzed. For day
7, two tumors were analyzed.
(E) Tet-TagLuc cells were treated in vitrowith dox or
were left untreated. After the indicated time points,
cells were stained with Annexin V and propidium
iodide (PI). Mean values from two experiments are
shown (±SD).
(F) Tet-TagLuc cells were cultured in the absence
or presence of dox as indicated, and indicated
proteins were analyzed by immunoblotting. Equal
protein loading was confirmed by b-actin detec-
tion. See also Figure S2. Error bars in (C–E)
represent ±SD.
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To elucidate themechanism of tumor cell decrease upon TagLuc
inactivation, Ki-67+ cells were enumerated over time, revealing
a loss of cell proliferation as early as 1 day following dox applica-
tion (Figures 6B and 6C). Surprisingly, cleaved Caspase3 (C3)+
cells did not increase but, if at all, decreased after TagLuc inac-
tivation, arguing against apoptotic cell death (Figures 6B and
6D). This was supported by in vitro experiments showing an
increase of Annexin V+/propidium iodide+ cells after TagLuc
inactivation, but not single Annexin V+ cells, as an intermediate
step during apoptotic cell death (Figure 6E). After 7 days of
dox treatment, cell numbers decreased by 83% (our unpub-
lished observation). However, 1 day after dox application, Tet-
TagLuc tumors strongly upregulated fibronectin expression
in vivo (Figure 6B). Expression of fibronectin has been associ-
ated with cell differentiation and cellular senescence, but it has
also been shown that fibronectin expression is upregulated byCancer Cell 20, 755–767, Dlight chain 3 (LC3) microtubule-associated
proteins (Ying et al., 2009). A shift of LC3
from a soluble to a membrane-bound
form (LC3-II) is a marker of autophagy
(Kabeya et al., 2000). TagLuc inactivation
in vitro led to a rapid increase in LC3-II
but not cleaved-C3 expression (Figure 6F).
Expression of p62 but not Beclin-1 gradu-
ally decreased over time (Figure S2). Thus,
TagLuc inactivation results primarily in au-
tophagic but not apoptotic cell death.In contrast, tumors from mice treated with TE cells 4 days
earlier contained largely viable tumor cells that stained positive
with antibodies against Tag, Luc, and Ki-67, consistent with
the BL imaging (Figure 6A). Few focal necrotic areas (less than
10%) were observed. These areas appeared to mark the begin-
ning of tumor eradication, as has been suggested (Blohm et al.,
2006). Areas of apparent tumor cell death stained positive for
cleaved-C3 but not Ki-67 or fibronectin (Figure 6B). Adjacent
tumor tissue revealed the opposite staining pattern, indicating
that the TE cells moved through the tumor in distinct clusters
leaving apoptotic tumor cells behind. On day 7, tumors were
completely necrotic (Figure 6A).
TE Cell Treatment but Not TagLuc Inactivation Destroys
the Tumor Vasculature
Macroscopically, regressing Tet-TagLuc tumors appeared dif-
ferently after dox and TE cell treatment, respectively. In contrastecember 13, 2011 ª2011 Elsevier Inc. 761
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Figure 7. TE Cell Treatment but Not TagLuc
Inactivation Leads to Destruction of the
Tumor Vasculature
(A) Tet-TagLuc tumor sections were stained for
the endothelial cell marker CD146 at the indicated
days (d) after start of therapy (scale bar, 100 mm).
See also Figure S3.
(B) Quantification of blood vessels (CD146+)
in sections of untreated (n = 3), dox-treated (d1 to
d3 and d7, n = 2; d4, n = 3) and TE cell-treated
(d4 and d7, n = 3) tumors (mean of 5 HPF at
400-fold magnification). Error bars represent ±SD.
***p 0.001; n.s. not significant (p 0.372); t test with
Bonferroni correction.
(C) IVMPM of blood vessels (red), extracellular
matrix (ECM; blue), and Annexin V+ cells (green)
subsequent to dox administration for time points as
indicated.
(D) IVMPM of blood vessels (red), adoptively
transferred CD8+ cells (blue), and Annexin V+ cells
(green) subsequent to adoptive T cell transfer for
time points as indicated. Scale bar, 100 mm.
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when BL signals had disappeared, pointing to differential effects
on the tumor vasculature (Figure S3). Immunohistochemical
analysis revealed that tumor blood vessels (CD146+) only slightly
(2-fold) decreased in Tet-TagLuc tumors 4 and 7 days after
oncogene inactivation (Figures 7A and 7B). At 4 days after TE
cell treatment, tumor vasculature was not significantly reduced.
Then, 7 days after TE cell transfer, the whole tumor tissue was
necrotic and endothelial cells were not detected anymore
(Figures 7A and 7B). Thus, a major difference between the two
therapies appears to be the destruction of the tumor vasculature,
in addition to tumor cells, by TE cells but not by drug therapy. To
directly visualize TE cells destroying tumor blood vessels, intra-
vital multiphoton microscopy (IVMPM) was used. Before treat-
ment, tight blood vessels were seen and no egression of762 Cancer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Inc.dextran-rhodamine was observed (Fig-
ure 7C). On day 3 after TE cell transfer,
T cells entered distinct areas of the tumor
in clusters but blood vessels remained still
intact (Figure 7D). After 4 and 5 days,
blood vessels were destroyed in areas of
T cell infiltration, as shown by egress of
dextran-rhodamine, and apoptotic (An-
nexin V+) cells became visible. Six days
after TE cell transfer, only T cells were
left and no dextran-rhodamine or Annexin
V+ cells were detectable, suggesting that
blood vessels and tumor cells are almost
simultaneously destroyed at sites of TE
cell infiltration. One and 2 days after dox
treatment, normal blood vessels and
extracellular matrix (ECM) fibers, indica-
tive of healthy tumor tissue, were ob-
served (Figure 7C). On day 6, tumors
contained abundant Annexin V+ cells and
absence of tensed ECM fibers, indicating
stromal instability as a result of tumorcell death. Blood vessels were largely retained, even though
some egress of dextran-rhodamine was observed, likely as a
consequence of vascular remodeling subsequent to tumor cell
death.
TE Cells Destroy the Tumor Vasculature and Long-Term
Reject Tumors Without Antigen Cross-Presentation
by Stroma Cells
Bystander elimination of escape variants by TE cells has been
shown to require antigen cross-presentation by tumor stroma
cells (Spiotto et al., 2004). In these models, as opposed to
ours, a non-cancer-driving antigen was used, which may allow
an easier selection of escape variants. Therefore, we asked
whether blood vessel destruction and tumor rejection by TE cells
required antigen cross-presentation. TE cells, sorted to high
BA
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Figure 8. Antigen Cross-Presentation Is Dispensable for Rejection of Large Tet-TagLuc Tumors by TE Cells
(A) SCID mice (H-2d) with established Tet-TagLuc tumors (mean ± SD, 521 ± 118 mm3 26 days after cell injection) were treated with H-2 Db restricted TE cells,
and changes of TagLuc signal were monitored by BL imaging (1 s exposure time). One representative example of 12 analyzed mice is shown. For comparison,
BL signal change in a tumor, growing in an identically treated Rag/ mouse (H-2b), is shown. See also Figure S4.
(B) Kinetics of tumor rejection in TE cell-treated (n = 12) or untreated SCID (n = 1) and TE cell-treated Rag
/ mice (n = 1).
(C) Tumors were isolated from untreated SCIDmice (n = 3) or 6 (n = 2) and 12 days (n = 1) after TE cell therapy and stained for the endothelial cell marker CD146.
(D) Rag/mice with established J558L-IFN-gIND tumors (mean ± SD, 200 ± 40 mm3 at day 7; n = 4) received 10 mg of dox i.p. for local IFN-g production. Integrity
of the tumor vasculature was analyzed at indicated time points after dox treatment by IVMPM.
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transferred into H-2d severe combined immune deficiency
(SCID) mice bearing large established H-2b Tet-TagLuc tumors,
so that the TE cells could recognize the antigen exclusively on the
tumor cells. Unlike in H-2b tumor-bearing Rag/mice, in which
BL signals started to decrease at day 5 after TE cell transfer andCanhad disappeared on day 7, BL signals did not decrease in SCID
mice until day 7. An example is shown in Figure 8A and all data in
Figure S4. Starting on day 9 after TE cell transfer, BL signals of
Tet-TagLuc tumors decreased in SCID mice and then became
undetectable, concomitant with long-term tumor rejection (Fig-
ure 8B) and expansion of the transferred (Db/peptide I tetramercer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Inc. 763
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with immune spleen cells isolated from TCR-I/Rag/ mice (our
unpublished observation). Compatible with the BL analysis,
CD146+ endothelial cells were present on day 6 after TE cell
transfer in Tet-TagLuc tumors but had been destroyed on day
12 (Figure 8C). Thus, blood vessel destruction and tumor rejec-
tion does not require antigen cross-presentation by tumor
stroma cells in the Tet-TagLuc model.
Local IFN-g Production Within Established Tumors
Is Sufficient for Rapid Blood Vessel Destruction
Finally, we asked how TE cells are able to destroy the tumor
vasculature without recognizing the tumor antigen on the tumor
stroma (e.g., endothelial cells). A major effector molecule by TE
cells is IFN-g, which is also produced by epitope I-specific TE
cells upon antigen recognition (our unpublished observation).
IFN-g can prevent recruitment of endothelial cells during estab-
lishment of solid tumors (Qin and Blankenstein, 2000; Qin et al.,
2003), but its effect on established tumor vasculature is less
clear. Therefore, we used a tumor cell line (J558L-IFN-gIND)
that allowed the induction of IFN-g in established tumors by
dox (Briesemeister et al., 2011). Thereby, wemimicked the effect
of a single TE cell-derived effector molecule on the tumor vascu-
lature, visualized by IVMPM in tumor-bearing mice injected with
dextran-rhodamine. Before dox treatment, tight blood vessels in
J558L-IFN-gIND tumors were observed and no dextran-rhoda-
mine leaked out of the vessels (Figure 8D). As early as 6 hr and
more markedly after 24 hr of local IFN-g induction by dox injec-
tion, dextran-rhodamine leaked from the blood vessel. After
48 hr, no dextran-rhodamine was observed in the tumors, indi-
cating that local induction of IFN-g in established tumors was
sufficient to rapidly destroy the tumor vasculature (Figure 8D).
DISCUSSION
We compared the efficacy of drug-induced oncogene inactiva-
tion versus T cell therapy against large tumors and defined
conditions that support or impede either form of therapy. Drug
therapy was modeled by dox-inducible inactivation of a fusion
protein between Tag and Luc, allowing sensitive in vivo imaging
of oncogene expression. Several transgenic models allowing
dox-controllable oncogene inactivation, such as myc, ras,
Her-2, and bcr-abl, have been described (Chin et al., 1999;
Felsher and Bishop, 1999; Huettner et al., 2000; Moody et al.,
2002). Similar to the Tet-TagLuc model, oncogene inactivation
always resulted in tumor regression, demonstrating that the
concept of oncogene addiction, the long-term dependency of
the tumor on a single oncogene, applies to a variety of different
oncogenes and tumor types (Jonkers and Berns, 2004; Wein-
stein, 2002). Primary tumors behaved similarly to transplanted
tumors (Felsher and Bishop, 1999). Drug-resistant tumors have
been observed in most models, albeit with variable frequency,
which could be due to tumor load (e.g., most small but not large
Tet-TagLuc tumors were successfully treated). Alternatively, it
may be inherent to the cancer-driving oncogene, differences in
the mode of tumor cell death upon oncogene inactivation, or
differences in tTA copy numbers. Drug-resistant tumors trans-
formed by ras, myc, or Her-2 in most cases did not express
the oncogene, indicating that dox regulation still functioned764 Cancer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Incand that these tumors had activated alternative transforming
pathways (Chin et al., 1999; Felsher and Bishop, 1999; Moody
et al., 2002). In contrast, we found inactivating point mutations
in the tTA gene and persistent TagLuc expression in all drug-
resistant Tet-TagLuc tumors. This could either mean that
TagLuc-transformed tumors are less prone to the activation of
alternate transforming pathways or exhibit more genetic insta-
bility (e.g., because of the p53 and Rb inactivating activity medi-
ated by Tag). In the clinic, both drug-inactivating mutations (e.g.,
in tyrosine kinase genes) and other mechanisms that do not
involve mutations in the target oncogene have been found under
drug therapy (Knight et al., 2010).
Current models of oncogene inactivation implicated apoptosis
in tumor regression. We failed to obtain evidence of apoptosis
in Tet-TagLuc cells following TagLuc inactivation. Instead, tumor
cell death was associated with autophagy. Autophagy has been
suggested as a survival and a death factor during drug therapy
(Kondo et al., 2005). The concomitant induction of autophagy
and tumor cell death within a few days after TagLuc withdrawal
suggests that autophagy contributed to tumor cell death, but we
cannot exclude that it also supported the selection of drug-resis-
tant clones. In previous models, apoptosis has been analyzed by
the TUNEL assay, which measures DNA fragmentation. How-
ever, the TUNEL assay does not distinguish between apoptotic
and nonapoptotic cell death. Therefore, it remains to be seen
whether oncogene inactivation-induced autophagic cell death
is a unique feature of TagLuc inactivation or whether it also
occurs for other oncogenes and whether the tumor cell type
influences the mode of antistress response caused by oncogene
withdrawal.
Two forms of non-cell autonomous effects during drug-in-
duced tumor cell death have been described. Cytotoxic drugs
were more efficient in T cell-competent compared to T cell-defi-
cient mice (Casares et al., 2005; Uckert et al., 1998). Although we
found indications of ‘‘immunogenic cell death’’ following TagLuc
inactivation in large tumors, only some of the mice rejected
the tumor in the presence of endogenous T cells, even though
the tumor expressed tTA as (skin graft) rejection antigen.
Recently, it was shown that CD4+ T cells sustained tumor regres-
sion upon myc inactivation (Rakhra et al., 2010). It is unclear why
tumor rejection after myc inactivation in the presence of T cells
was more efficient, because this model differed from ours in
several factors, such as tumor type (lymphoma versus sarcoma),
genetic background (FVB versus B6 mice), experimental setup,
and, possibly, tumor immunogenicity. In both tumor models,
Luc and tTA were expressed as foreign antigens, but it is
unknown how immunogenic the two antigens are in FVB mice.
We think that the time the tumor had grown before oncogene
inactivation is a critical factor, whether or not tumor cell death
is immunogenic, because the frequently observed tumor-
induced T cell tolerance requires a certain time of antigen expo-
sure. In this regard, both the myc-driven and the Tag-driven
model do not reflect the clinical situation, in which T cells are
exposed to the tumor for a longer time. Although human tumors
carry many mutations and, thus, potentially foreign antigens, it is
not known how many are in fact immunogenic and how strong
they are. Proof of ‘‘immunogenic cell death’’ upon oncogene
inactivation in the clinic is still lacking. A second non-cell autono-
mous effect, reported in a model of ras inactivation, is the.
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tumors (Chin et al., 1999; Tang et al., 2005).Wealso noted a slight
(2-fold) reduction in the number of endothelial cells, but large
numbers were still present when most tumor cells had disap-
peared at 7 days after TagLuc inactivation.
Each drug-resistant Tet-TagLuc tumor carried a unique inacti-
vating mutation in the tTA gene, caused by the high genetic
instability of the cancer cells and the stochastic accumulation
of mutations with increasing tumor burden. Therefore, variants
with mutations in epitope I, loss of MHC class I, or those employ-
ing other escapemechanisms (Gooding, 1982; Mylin et al., 2007)
likely also occurred in large Tet-TagLuc tumors. However, the
major difference in tumor elimination by TagLuc inactivation
and TE cell therapy appeared to be the complete destruction of
the tumor vasculature and probably the whole tumor stroma by
TE cells, whereas TagLuc inactivation selectively killed the
cancer cells but left most endothelial cells alive. We propose
that variants that escaped drug therapy have a high chance to
survive, because they are embedded in a vital stroma. In
contrast, within the TE cell-induced necrotic tumor tissue
immune escape variants are unlikely to survive.
‘‘Bystander killing’’ of antigen loss variants required enough
amounts of antigen for cross-presentation by tumor stroma cells
and IFN-g, which is produced by T cells upon antigen recogni-
tion, acting on stroma cells (Spiotto et al., 2004; Zhang et al.,
2008). Compatible with these data, antigen loss variants of
comparably small MCA-TagLuc tumors that expressed TagLuc
in lower amounts and in a non-cancer-driving fashion compared
to Tet-TagLuc and TC200.09 cells escaped TE cells. Surprisingly,
complete rejection of large Tet-TagLuc tumors did not require
antigen cross-presentation by tumor stroma cells. Infiltration of
Tet-TagLuc tumors by large numbers of TE cells started in
distinct tumor areas, where apoptosis of tumor cells and blood
vessel destruction occurred simultaneously. Previously, it was
shown in a model with low numbers of tumor cells (3-day-old
B16-Ova cells) that antigen recognition by TE (OT-1) cells on
the tumor cells was sufficient to eliminate the tumor cells, which
required IFN-g responsiveness of host cells (Schu¨ler and Blan-
kenstein, 2003). This was explained by a three-cell interaction,
in which TE cells upon antigen recognition on the tumor cells
produced IFN-g, which inhibited endothelial cells and prevented
tumor establishment (Blankenstein, 2005). Because IFN-g
expression in established tumors was sufficient to rapidly
destroy the tumor vasculature, we suggest that, in the Tet-
TagLuc tumor model, antigen recognition by TE cells on the
tumor cells induces cytokines such as IFN-g or TNF-a (Zhang
et al., 2008), which destroy the tumor vasculature, thereby
inducing necrosis and elimination of escape variants. It is unclear
why such a three-cell interaction and cytokine-mediated blood
vessel destruction was not operative in MCA-TagLuc tumors or
other tumor models (Spiotto et al., 2004). The type of antigen
(epitope), the quality of the TE cells, antigen amount-dependent
effector functions of the TE cells in the tumor microenvironment,
the cancer-driving nature of the target antigen, or a combination
of these factors may account for the differences.
With regard to drug therapy and resistance, our model bears
large similarities to the clinical situation. Human cancer is
frequently characterized by genetic instability. Resistance to
drugs, which target oncogenic pathways, is a common obser-Canvation in the clinic. The treatment of large clinical-size tumors
and the drug resistance caused by the high genetic instability
in our model closely resembles the clinical experience. With
regard to TE cell therapy, our model only partially resembles
the clinical experience. Although individual cases of long-term
regression have been observed, immune escape in patients
with melanoma upon TE cell therapy frequently occurs (Restifo
et al., 1996; Yee et al., 2000). By targeting a cancer-driving viral
oncogene in a lymphopenic host, we created an ideal situation
of TE cell therapy, which, however, at least partially can be
extrapolated into the clinic. In our model, TE cells recognized
the target antigen as foreign and were of high avidity, whereas
in the current clinical trials, TE cells were directed against
tumor-associated (self) antigens (TAAs) isolated from the
tolerant repertoire, which likely yields predominantly low-avidity
TE cells. This may be one reason why tumors escape TE cell
therapy in patients but not in our model. However, the possibility
to select high-affinity human T cell receptors (TCRs) against
any human TAAs from the nontolerant repertoire (Li et al.,
2010) and their use for TCR gene therapy (Schumacher, 2002)
might allow engineering of TE cells in the future for clinical
use, which may be as effective as TCR-I TE cells against Tet-
TagLuc tumors. Another reason that TE cell therapy is so effec-
tive in our model may be because we targeted a viral cancer-
driving oncogene, which makes immune escape more difficult.
Cancer-driving antigens have not been targeted by TE cell
therapy in the clinic, which might be possible with Merkel cell
carcinoma, a rare disease caused by an SV40-related polyoma-
virus containing a homologous Tag (Feng et al., 2008).
Currently, it is unknown whether the TE cell therapy of fibrosar-
coma and gastric carcinoma, albeit employed with large estab-
lished tumors, is similarly effective in models of primary (non-
transplanted) tumors. It also needs to be seen whether and
under which conditions TAAs, whose expression is often not
necessary for a malignant phenotype, can be targeted with
similar efficacy in the clinic by TE cells as shown here for
TagLuc. In conclusion, adoptive T cell therapy and drug-based
cancer treatment were both highly effective in mouse models of
fibrosarcoma and gastric carcinoma, but only T cells killed
cancer cells and simultaneously destroyed the tumor vascula-
ture, which may be critical to prevent escape.EXPERIMENTAL PROCEDURES
Mice
Rag-1/ or Rag-2/ (Rag/) mice and TCR-Imice, which are transgenic for
an H-2-Db-restricted Tag epitope I-specific (Vb7+) T cell receptor (Staveley-
O’Carroll et al., 2003), were obtained from The Jackson Laboratory. Rag//
OT-1 and CB17/lcrPrkdcscid/lcrlcoCrl (SCID) mice were obtained from Taconic
and Charles River, respectively. LoxP-Tag 3 Alb-Cre mice have been
described elsewhere (Willimsky et al., 2008). As skin graft donors, rtTA-CM2
transgenic mice expressing the reverse transactivator rtTA2S-M2 and
CAG-Fluc mice expressing the firefly luciferase (Fluc), both controlled by the
CAG promoter, on an albino B6 genetic background (unpublished data)
were used. Generation of TREloxPstoploxPTagLuc transgenic mice is described
in Supplemental Experimental Procedures. These mice express a dox-induc-
ible TagLuc fusion gene (Buschow et al., 2010), which is separated from the
TRE promoter by a loxP site-flanked stop cassette. All animal experiments
were conducted in accordance with institutional and national guidelines
and regulations, after approval by the Landesamt fu¨r Gesundheit und Soziales
(Berlin).cer Cell 20, 755–767, December 13, 2011 ª2011 Elsevier Inc. 765
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Cells were cultured in Dulbecco’s modified eagle medium (GIBCO), supple-
mented with 10% heat-inactivated fetal calf serum (PAN, Biotech) and
50 mg/ml gentamicin (GIBCO). Tet-TagLuc cells were derived from tail
fibroblasts of a TREloxPstoploxPTagLuc heterozygous mouse. Fibroblasts
were isolated by collagenase digestion (type II, Invitrogen) and after three
culture passages were infected with adenoviruses and retroviruses, encoding
the Cre recombinase (Willimsky and Blankenstein, 2005) and the Tet-off trans-
activator (tTA, Clontech, #631003), respectively. Cells at passage 19 were
injected subcutaneously (s.c.) into a Rag/mouse, and a cell line was estab-
lished from the resulting tumor. MCA205 fibrosarcoma cells were cotrans-
fected with pCAG-TagLuc (Buschow et al., 2010) and pMSCVpuro (Clontech)
plasmid DNA (ratio 10:1) with lipofectamine 2000 reagent (Invitrogen), selected
for puromycin (Sigma) resistance (10 mg/ml), and TagLuc-expressing clones
were identified by Fluc activity. A cell line (TC200) of a gastric carcinoma,
grown in a TREloxPstoploxPTagLuc 3 rtTA-CM2 mouse, was established and
passaged once in a Rag/ mouse (TC200.09). J558-IFNgIND cancer cells
were described previously (Briesemeister et al., 2011). Between 1 and 53 106
tumor cells were s.c. injected into mice as indicated. Tumor growth and
regression, respectively, were analyzed by BL imaging and determination of
tumor volume by caliper measurement according to the formula (xyz)/2.
Adoptive T Cell Transfer
CD8+ T cells of TCR-I mice were isolated by negative magnetic-activated cell
sorting (Miltenyi Biotec, #130-090-859) 7 days after immunization with 13 107
Tag+ 16.113 cells (Willimsky and Blankenstein, 2005) and 1 3 106 cells were
injected intravenously (i.v.) into mice. T cells were analyzed by flow cytometry
with anti-CD8a (RM4-5) and anti-Vb7 antibodies (BD PharMingen) and peptide
I/Db tetramers (Beckman-Coulter). Alternatively, 1 3 107 splenocytes of
LoxP-Tag x Alb-Cremice were injected i.v. into Rag//OT-1mice. Blood cells
were stained with anti-CD8a and anti-Vb5 (MR9-4) antibodies and analyzed by
flow cytometry.
Doxycycline Treatment
Dox (0.2–1 mg/ml; Sigma) was administered by light-protected drinking water
supplemented with 5% sucrose twice a week, or 0.5–1 mg/ml dox was added
to the cell culture medium every 2 days.
Bioluminescent Detection
Mice received 3 mg of D-luciferin (Biosynth) i.p., dissolved in PBS (30 mg/ml).
After 10 min, mice were anesthetized by Isofluran and imaged. The exposure
time for BL image acquisitionwas 1 s or 60 s, depending on the signal strength.
The BL imaging data were analyzed with Living Image software (Caliper Life
Science). For in vitro cell culture, 1 3 106 cells were seeded in duplicates in
96-well-plates, D-luciferin was added to the cell culture medium (15 mg/ml),
and luciferase activity was quantified using a Mithras LB 940 luminometer
(Berthold Technologies).
Skin Transplantation
Transplantation of full thickness skin grafts was performed by standard
procedure.
IVMPM
Imaging procedures were performed as described previously (Herrmann et al.,
2010). Briefly, mice received 100 mg of dextran-rhodamine (Invitrogen) and
10 mg of Annexin V-FITC (BioVision) or 250 mg of Hoechst dye 15 min prior
to imaging. Signals of the extracellular matrix are given by second harmonic
generation. Fluorescent emission was acquired using an Ultima Multiphoton
Microscopy System (Prairie Technologies). T cells were labeled with 5 mM
CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin; Invitrogen) before
transfer.
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